Exactech, Inc announced the successful initial implantation of
Optecure in a recent spinal fusion surgery.
The surgery was performed by Hansen Yuan, M.D., professor of orthopaedic
and neurological surgery and director of spine research at the State
University of New York. He reported that Optecure worked well as a bone graft
extender for spinal fusion, was easy to use and mixed well with autogenous
Optecure is demineralized bone matrix (DBM) in a synthetic bioabsorbable
polymer carrier. It was the first FDA-cleared medical device that includes
human DBM as a component.
Exactech Chairman and CEO Bill Petty, M.D., said, "The introduction of
Optecure is an important step in Exactech's strategy to strengthen its focus
on biologic solutions to orthopaedic problems. Both the product and the
manufacturing process have been designed and validated by Exactech. Providing
materials for use in the spine enables us to improve the lives of a wider
variety of patients."
Earlier this month, Exactech introduced OpteMx, another biomaterial
designed for spinal and general orthopaedic applications. This engineered
composite chemically and structurally mimics cancellous bone, providing a
conductive scaffold for bone restoration.
More than 100,000 surgeries a year are performed in the U.S. using
demineralized bone matrix products in a market valued at approximately
$200 million. The spinal segment of this bone paste market is estimated to be
$100 million. The market for all applications of synthetic biomaterials is
estimated to be $75 million.